Cost- Effectiveness of Real Life Asthma Pharmacotherapy

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.2057
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

RS2 Cost-Effectiveness of End-Of-Life, Life-Extending Interventions: NICE's Cost-Effectiveness Threshold Explored

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Cost Effectiveness of Mepolizumab in Adult Asthma Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Real-Life Effectiveness of Omalizumab in Severe Allergic Asthma Above the Recommended Dosing Range Criteria

Pediatrics
Child HealthPediatricsPerinatology
2017English

Cost-Effectiveness of Pharmacotherapy for Children and Adolescents With Attention Dificit Hyperactivity Disorder

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

A Bayesian Dynamic Model of Asthma in the Real Life

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Prs55 - Cost-Effectiveness of Mepolizumab in Severe Eosinophilic Asthma Patients in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P170 Long-Term Effectiveness of Omalizumab in Patients With Severe Persistent Allergic (IgE-mediated) Asthma: UK Centre Real-Life Experience

Thorax
PulmonaryRespiratory Medicine
2013English

Pharmacotherapy for Late-Life Depression

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2011English

Loss of Asthma Control After Cessation of Omalizumab Treatment: Real Life Data

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy